Stock Analysis on Net

Altria Group Inc. (NYSE:MO)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 31, 2024.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Altria Group Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Short-term borrowings
Current portion of long-term debt
Accounts payable
Marketing
Settlement charges
Other
Accrued liabilities
Deferred gain from the sale of IQOS System commercialization rights
Dividends payable
Liabilities held for sale
Current liabilities
Long-term debt, excluding current portion
Deferred income taxes
Accrued pension costs
Accrued postretirement health care costs
Deferred gain from the sale of IQOS System commercialization rights
Other liabilities
Non-current liabilities
Total liabilities
Redeemable noncontrolling interest
Common stock, par value $0.33 1/3 per share
Additional paid-in capital
Earnings reinvested in the business
Accumulated other comprehensive losses
Cost of repurchased stock
Stockholders’ equity (deficit) attributable to Altria
Noncontrolling interests
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Short-term borrowings
The percentage of short-term borrowings in relation to total liabilities and stockholders’ equity is sparsely reported but shows a value of 5.7% in June 2020 and declines slightly to 5.38% as of March 2024, suggesting limited reliance on this form of financing in recent quarters.
Current portion of long-term debt
The proportion fluctuates moderately over the quarters, starting at 3.62% in March 2019, peaking around 7.17% in June 2022, and moving back to approximately 4.64% by September 2024. This indicates some variability in near-term debt obligations.
Accounts payable
This item shows a generally increasing trend, rising from 0.35% in March 2019 to around 1.49% in September 2024, with some fluctuations. The increase implies a growing amount of short-term operational liabilities.
Marketing
Marketing expenses as a percentage of total liabilities and stockholders’ equity trends upward from 0.83% in March 2019 to 2.39% in September 2024, indicating increased investment in marketing efforts over the periods.
Settlement charges
Settlement charges exhibit volatility, with peaks around 10.51% in March 2022 and troughs near 3.84% in June 2024. The cyclical pattern may reflect episodic or irregular settlement-related costs.
Other liabilities
Other liabilities show a gradual increase from 2.38% in March 2019 to a peak around 5.53% in June 2024 before falling back to 3.59% in September 2024, signifying occasional changes in miscellaneous liabilities.
Accrued liabilities
Accrued liabilities also experience fluctuations, moving up from 10.58% in March 2019 to 16.56% in March 2024, with odd dips. This suggests variations in expenses incurred but not yet paid.
Dividends payable
Dividends payable steadily increase over the period, from 2.53% in March 2019 to 5.09% in September 2024, evidencing growing commitments to shareholder distributions.
Current liabilities
Current liabilities fluctuate substantially but show an overall rising tendency, notably from 17.08% in March 2019 to levels around 23.4% by mid-2024, peaking at 31.4% in June 2023, indicating variations in short-term obligations.
Long-term debt, excluding current portion
Long-term debt consistently represents a significant portion of liabilities and equity, increasing from 45.62% in March 2019 to around 68.98% by September 2024, reflecting increased use of long-term leverage.
Deferred income taxes
This item remains relatively stable, hovering near 9-10%, suggesting consistent deferred tax liabilities.
Accrued pension and postretirement healthcare costs
Both accrued pension costs and accrued postretirement healthcare costs remain low and stable with minor fluctuations, implying steady long-term benefit obligations.
Other liabilities (excluding ‘Other’)
Other liabilities rise notably from under 1% in early periods to values near 4.67% by 2024, indicating increased miscellaneous long-term liabilities.
Non-current liabilities
Non-current liabilities consistently make up a growing share of total liabilities and equity, moving from approximately 59% in early 2019 to over 86% by late 2024, highlighting a shift toward long-term financing and obligations.
Total liabilities
Total liabilities steadily increase as a percentage of the aggregate, climbing from 76.16% in March 2019 to near 110% in recent quarters, which reflects increasing leverage relative to stockholders’ equity.
Redeemable noncontrolling interest
This component remains negligible throughout the period, generally below 0.1%.
Common stock and additional paid-in capital
Common stock increases modestly from 1.58% to approximately 2.74%, while additional paid-in capital shows a steady increase from 10.03% to around 17.24%, indicating moderate growth in contributed capital.
Earnings reinvested in the business
The percentage of earnings reinvested in the business fluctuates but exhibits an overall upward trend from 73.58% in 2019 to surpassing 100% by September 2024. This suggests increasing retained earnings, which may offset other equity declines.
Accumulated other comprehensive losses
Accumulated other comprehensive losses remain negative throughout but show some volatility, generally around -4.5% to -7.6%, reflecting ongoing unrealized losses affecting equity.
Cost of repurchased stock
The cost of repurchased stock expands notably from -56.83% to over -122%, indicating substantial and increasing buyback activity over the years, which reduces equity.
Stockholders’ equity
Stockholders’ equity shows a marked decline from a positive 23.77% in March 2019 to negative territory after 2021, reaching below -10% in recent quarters. This significant erosion of equity is associated with increased liabilities and aggressive stock repurchases.
Total stockholders’ equity (deficit)
The total stockholders’ equity follows the same negative trend, reflecting a deficit that intensifies over the years, suggesting financial strain or strategic capital restructuring.
Summary
Overall, the data reveals a pattern of increasing leverage, driven by rising long-term debt and non-current liabilities, combined with a declining equity base that turns negative. Concurrently, marketing and dividend obligations increase, while significant stock repurchases reduce equity. The company exhibits heightened short-term liabilities and fluctuating settlement charges, with deferred tax liabilities and pension obligations remaining stable. These trends indicate a growing reliance on debt financing and a challenging equity situation over the analyzed periods.